In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.

@article{Yum2007InVA,
  title={In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.},
  author={Jong Hwa Yum and Chang Ki Kim and Dongeun Yong and Kyungwon Lee and Y. Chong and Cheol Min Kim and Jeong Mi Kim and Seonggu Ro and Joong Myung Cho},
  journal={Antimicrobial agents and chemotherapy},
  year={2007},
  volume={51 7},
  pages={2591-3}
}
The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin. 

1 Figure or Table